Molecular structure of LY2109761, CAS Number: 700874-71-1
LY2109761 (CAS 700874-71-1)
See product citations (9)
Alternate Names:
4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]-quinoline
Application:
LY2109761 is a small molecule inhibitor of the TGF-β receptor type 1/type II kinases
CAS Number:
700874-71-1
Purity:
≥98%
Molecular Weight:
441.52
Molecular Formula:
C26H27N5O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
LY2109761 is a chemical compound utilized in the field of biochemistry and cell biology for its role as an inhibitor of transforming growth factor-beta (TGF-β) receptor kinases. This inhibition is of interest in studies investigating the signaling pathways that influence cell proliferation, differentiation, and migration. LY2109761 helps identify the complex processes of cellular communication and regulation by selectively targeting and modulating the TGF-β pathway. The compound′s mechanism of action involves the prevention of phosphorylation events that are typically induced by TGF-β, thereby modulating downstream effects. LY2109761 is utilized in dissecting the TGF-β signaling cascade and for exploring the molecular mechanisms underlying various biological responses to TGF-β. It is also in studies that examine the role of TGF-β signaling tissue homeostasis.
LY2109761 (CAS 700874-71-1) References
- Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. | Li, HY., et al. 2008. J Med Chem. 51: 2302-6. PMID: 18314943
- LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. | Melisi, D., et al. 2008. Mol Cancer Ther. 7: 829-40. PMID: 18413796
- Dual-responsive nanosystem based on TGF-β blockade and immunogenic chemotherapy for effective chemoimmunotherapy. | Huang, X., et al. 2022. Drug Deliv. 29: 1358-1369. PMID: 35506467
- TGF-β-Induced FLRT3 Attenuation Is Essential for Cancer-Associated Fibroblast-Mediated Epithelial-Mesenchymal Transition in Colorectal Cancer. | Yang, M., et al. 2022. Mol Cancer Res. 20: 1247-1259. PMID: 35560224
- Dietary intake of GDF11 delays the onset of several biomarkers of aging in male mice through anti-oxidant system via Smad2/3 pathway. | Song, L., et al. 2022. Biogerontology. 23: 341-362. PMID: 35604508
- Effect of ALA-PDT on inhibition of oral precancerous cell growth and its related mechanisms. | Jin, JQ., et al. 2022. Lasers Med Sci. 37: 3461-3472. PMID: 35796919
- Puerarin protects fibroblasts against mechanical stretching injury through Nrf2/TGF-β1 signaling pathway. | Li, Y., et al. 2022. Int Urogynecol J. 33: 2565-2576. PMID: 35962806
- Salidroside alleviates dexamethasone-induced inhibition of bone formation via transforming growth factor-beta/Smad2/3 signaling pathway. | Xie, B., et al. 2023. Phytother Res. 37: 1938-1950. PMID: 36567454
- Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma. | Al-Holou, WN., et al. 2023. Neoplasia. 36: 100872. PMID: 36621024
- Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF-β/SMAD pathway. | Luo, D., et al. 2023. J Cell Mol Med. 27: 456-469. PMID: 36651490
- Gallium-modified gelatin nanoparticles loaded with quercetin promote skin wound healing via the regulation of bacterial proliferation and macrophage polarization. | Yang, N., et al. 2023. Front Bioeng Biotechnol. 11: 1124944. PMID: 36777248
- An immune and epithelial-mesenchymal transition-related risk model and immunotherapy strategy for grade II and III gliomas. | Luo, W., et al. 2022. Front Genet. 13: 1070630. PMID: 36778912
- FUT1-mediated terminal fucosylation acts as a new target to attenuate renal fibrosis. | Luo, J., et al. 2023. Mol Med. 29: 55. PMID: 37085770
- Dual Blockade of TGF-β Receptor and Endothelin Receptor Synergistically Inhibits Angiotensin II-Induced Myofibroblast Differentiation: Role of AT1R/Gαq-Mediated TGF-β1 and ET-1 Signaling. | Duangrat, R., et al. 2023. Int J Mol Sci. 24: PMID: 37108136
- Circ_0020256 induces fibroblast activation to drive cholangiocarcinoma development via recruitment of EIF4A3 protein to stabilize KLF4 mRNA. | Li, Z., et al. 2023. Cell Death Discov. 9: 161. PMID: 37179359
- Crosstalk between the JAK2 and TGF-β1 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib. | Wang, D., et al. 2023. Adv Rheumatol. 63: 22. PMID: 37194022
Inhibitor of:
β ig-h3, ACTR-IIA, BMPR-IB, C2orf70, CCBE1, COL1A1, COL5A3, Cryptic, Cypt4, DAF-1, EMILIN-1, Fussel-18, GDF-1, GDF-9, gremlin-2, Hic-5, Inhibin β-E, LOC645781, LOC646862, LRRC32, LRRC72, MUP20, Nodal, NOMO2, NPN, Oct-6, PMEPA1, POU3F, POU3F4, PTGF-β, RGMb, SARA, Smad2, Smad7, SNIP1, SUSD4, TBCK, TGF B3, TGF beta Receptor, TGF beta RI, TGFβ RII, TGFβ RIII, TGFβ2, TGFβ3, TGIF2LX1, TGIF2LX2, TIAF-1, Vasorin, Vmn1r170, Vmn1r39, Vmn1r94, and ZNF865.Activator of:
CD109, CD77 synthase (A4GALT), COL2A1, EG625464, Fibroblast Marker, Fibulin-3, Helios, LAP, Lefty-2, LRRC15, LTBP-1, Smad5, SnoN_SnoN2_SnoA, TGF B-1, TSC-36, and VSTM5.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LY2109761, 1 mg | sc-396262 | 1 mg | $87.00 | |||
LY2109761, 5 mg | sc-396262A | 5 mg | $270.00 |